In the center of the Johnson & Johnson Coronavirus Vaccine Jungle, producer Emergent Biosolutions gave its chief executive a 51 percent compensation bump in 2020.
As of late Friday with the company’s Securities and Exchange Commission, with a lucrative $ 893,000 salary, CEO Robert Kramer received a $ 1.2 million bonus and $ 3.5 million in stock awards and options.
Emergent’s response to the COVID-19 epidemic last year contributed to Kramer’s juice-up compensation package, citing the company expanding its contract manufacturing business.
Maryland-based biopharmaceutical company increased revenue by 41 percent in 2020 after printing vaccine manufacturing deals with Jammu and Kashmir and AstraZeneca at its Baltimore plant.
Its success was also largely overcome by a massive $ 628 million federal contract in upgrades and reserve capacity to meet government vaccine orders and fight the epidemic.
But Emergent’s problems became public on March 31, after a mixed effect at its Baltimore plant contaminated Jammu and Kashmir’s vaccine – 15 million wastes of single-dose shots.
The screw-up has now delayed the Food and Drug Administration’s certification of the Baltimore facility, According to the washington post
.
The plant is not currently authorized to supply J & J to the Americans – all one-dose jabs from J & J’s own plant in the Netherlands have been excluded in the US, which is authorized by the end of February. Was received
The outlet said the mistake led the federal government to remove all of AstraZeneca’s vaccine production.
As a result, the government has cut the amount of Jammu and Kashmir vaccines allocated to the states, and the company returned its pledge to deliver 24 million doses of vaccines to the federal government in April.
Meanwhile, it was revealed earlier this month that Emergent has been embroiled in quality control problems for some time.
According to records obtained by the Associated Press through the Freedom of Information Act, the FDA has repeatedly cited a myriad of companies for potentially dangerous issues, such as poorly trained employees, broken vials, and problems in managing mold and other contamination. . . The records have been inspected at Emergent facilities since 2017.
Emergent has not publicly put the issues in any detail, but it Told the Washington Post It has hosted the FDA several times at its facility.
Those visits included a “review of progress on items cited in previous FDA visits”, the company told the outlet.
However, in response to the latest manufacturing issues, Amergent has received $ 23 million more from the US Biomedical Advanced Research and Development Authority to purchase vaccine manufacturing equipment and expand its Jammu and Kashmir production.
“Emergent’s top priority is for Johnson & Johnson to continue to strengthen the supply chain for the COVID-19 vaccine,” Kramer said. “” We are working closely with Johnson & Johnson and welcome additional oversight and support at our Bayview facility. “
Leave a Reply